Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 43.39K shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 165.60K shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 382.22K shares, a 15.90% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 43.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 0.00 shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-12 | 0.00 shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 0.00 shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | 30.00K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 165.60K shares 10-K · filed 2025-03-31 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 165.60K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | 30.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 165.60K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-03-31 | 135.60K shares 10-Q · filed 2023-05-09 | 135.60K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 0.00 shares 10-K · filed 2024-03-28 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 75.11K shares derived: sum of 4 quarters · filed 2023-03-21 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 188.86K shares derived: sum of 4 quarters · filed 2023-03-21 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-10 | 251.58K shares derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-12-31 | 75.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | 382.22K shares 10-K · filed 2023-03-21 |
| 2021-09-30 | 113.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 383.86K shares derived: sum of 4 quarters · filed 2022-03-16 |
| 2021-06-30 | 62.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 371.23K shares derived: sum of 4 quarters · filed 2022-03-16 |
| 2021-03-31 | 130.64K shares 10-Q · filed 2021-05-10 | 571.36K shares derived: sum of 4 quarters · filed 2022-03-16 |
| 2020-12-31 | 76.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 454.50K shares 10-K · filed 2022-03-16 |
| 2020-09-30 | 101.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 674.95K shares derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-06-30 | 262.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 669.68K shares derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-03-31 | 13.78K shares 10-Q · filed 2020-05-07 | 413.09K shares derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-12-31 | 297.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | 485.11K shares 10-K · filed 2021-03-09 |
| 2019-09-30 | 95.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 187.90K shares derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-06-30 | 6.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | |
| 2019-03-31 | 85.79K shares 10-Q · filed 2019-05-08 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 2.50K shares 10-K · filed 2020-03-12 |
| 2017-12-31 | 2.80K shares 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |